A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

Exclusion Criteria

• •History of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
• •Participants with any of the following respiratory conditions:
• •* Evidence of noninfectious interstitial lung disease (ILD) or pneumonitis that:
• •* \* Was previous diagnosed and required systemic steroids, or
• •* \* Is currently diagnosed and managed, or
• •* \* Is suspected on radiologic imaging at screening
• •* Known diffusing capacity of the lung for carbon monoxide (DLCO) \< 50%
• •* Any Grade greater than or equal to (≥) 3 pulmonary disease unrelated to underlying malignancy
• •* Prior radiation therapy to the lung that is \>30 gray (Gy) within 6 months of the first dose of sigvotatug vedotin.
• •Pre-existing peripheral neuropathy Grade greater than or equal to (≥) 2
• •Uncontrolled diabetes mellitus
• •Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they:
• •* are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment,
• •* have no new or enlarging brain metastases, and
• •* are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to first dose of study drug.
• •Known history or current diagnosis of carcinomatous meningitis
• •Previous treatment with an MMAE-containing agent or an agent targeting integrin beta-6
• •Prior anticancer therapies:
• •* Chemotherapy within 21 days prior to first administration of sigvotatug vedotin
• •* Targeted small molecule agents within 14 days or 5 half-lives (whichever is longer) prior to first administration of sigvotatug vedotin
• •* Antibody-based anticancer or other investigational antitumor therapy within 28 days prior to first administration of sigvotatug vedotin
• •* Focal radiotherapy or major surgery that is not completed 14 days prior to the first dose of sigvotatug vedotin
• •Traditional or herbal medicines:
• •* Anti-cancer traditional or herbal medicines within 28 days prior to first administration of sigvotatug vedotin
• •* Traditional or herbal medicines for other purposes (such as supportive care) within 7 days prior to first administration of sigvotatug vedotin